Content area

|
|

Glukagonlignende peptid 1-receptoragonisten semaglutid

Forfatter(e)
Amalie Dyhrberg Boje1, Christian Rimer Juhl1, Signe Sørensen Torekov1 & Sten Madsbad2 1) Biomedicinsk Institut, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet 2) Endokrionologisk Afdeling,
Hvidovre Hospital

Ugeskr Læger 2019;181:V03190155
Reference: 
Ugeskr Læger 2019;181:V03190155
Blad nummer: 

Amalie Dyhrberg Boje, Christian Rimer Juhl,
Signe Sørensen Torekov & Sten Madsbad:

The glucagon-like peptide-1 receptor-agonist semaglutide

Ugeskr Læger 2019;181:V03190155

Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes. Trials with semaglutide have demonstrated superiority with sustained improved glycaemic control and weight loss compared to oral antidiabetic agents, other GLP-1 RAs and basalinsulin. In addition, semaglutide significantly decreased the occurrence of cardiovascular events compared with standard pharmacological diabetic treatment combined with placebo.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Holger Ahler M. Therkildsen | 29/09
1 Kommentar
af Mats Lindberg | 29/09
1 Kommentar
af Anne Amalie Elgaard Thorup | 28/09
1 Kommentar
af Henrik Harboe | 28/09
1 Kommentar
af Svend Nielsen | 27/09
4 kommentarer
af Nini Katja Møller | 26/09
1 Kommentar
af Niels Rud Haagensen | 25/09
10 kommentarer